Corpus overview


MeSH Disease

Human Phenotype


There are no transmission terms in the subcorpus


There are no seroprevalence terms in the subcorpus

    displaying 1 - 1 records in total 1
    records per page

    Safety and Efficacy Concerns of Lopinavir/Ritonavir in COVID-19 MESHD Affected Patients: A Retrospective Series

    Authors: Marc-Antoine Lepage; Nicholas Rozza; Richard Kremer; Ami Grunbaum

    doi:10.1101/2020.07.23.20153932 Date: 2020-07-27 Source: medRxiv

    Context: Originally developed for the treatment of human immunodeficiency virus MESHD immunodeficiency HP virus ( HIV MESHD), the antiviral combination lopinavir/ritonavir (LPV/r) is being investigated for use against coronavirus disease ( COVID-19 MESHD). We present a case series raising safety and efficacy concerns in COVID-19 MESHD affected patients. Methods: We measured LPV trough concentrations in 12 patients treated at our center and reviewed their clinical charts for side effects known to occur in HIV MESHD patients. Results: Compared to established LPV trough concentrations in HIV MESHD treated patients, concentrations in COVID-19 MESHD affected patients were 3-fold greater (20.64 +/- 10.14 mcg/mL versus 6.25 mcg/mL). In addition, cholestasis MESHD cholestasis HP and dyslipidemia toxicity MESHD thresholds were exceeded in 12/12 and 11/12 patients respectively. No patients achieved the presumed therapeutic concentration. The side effects noted were mainly gastrointestinal symptoms (5/12, 42%), electrolytes imbalances (4/12, 33%), liver enzyme disturbances MESHD (5/12, 42%), and triglyceride elevations (2/12, 17%). Conclusion: None of our patients reached presumed therapeutic LPV concentrations despite experiencing side effects and exceeding cholestasis HP cholestasis MESHD and dyslipidemia toxicity MESHD thresholds. This raises concerns for the safety and efficacy of LPV/r. Clinicians should consider closely monitoring for side effects and not necessarily attribute them to COVID-19 MESHD itself.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.